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Abstract
Objectives: to establish and quantify any observable association between the exposure to community prescriptions for quinine
and acute kidney injury (AKI) events in a population of older adults.
Design: two observational studies using the same dataset, a retrospective longitudinal cohort study and a self-controlled case
series (SCCS).
Setting: NHS health board in Scotland.
Participants: older adults (60+ years) who received quinine prescriptions in Tayside, Scotland, between January 2004 and
December 2015. The first study included 12,744 individuals. The SCCS cohort included 5,907 people with quinine exposure
and more than or equal to one AKI event.
Main outcome measured: in the first study, multivariable logistic regression was used to calculate odds ratios (ORs) for AKI
comparing between episodes with and without recent quinine exposure after adjustment for demographics, comorbidities
and concomitant medications. The SCCS study divided follow-up for each individual into periods ‘on’ and ‘off’ quinine,
calculating incidence rate ratios (IRRs) for AKI adjusting for age.
Results: during the study period, 273,596 prescriptions for quinine were dispensed in Tayside. A total of 13,616 AKI events
occurred during follow-up (crude incidence 12.5 per 100 person-years). In the first study, exposure to quinine before an
episode of care was significantly associated with an increased probability of AKI (adjusted OR = 1.27, 95% confidence interval
(CI) 1.21–1.33). In the SCCS study, exposure to quinine was associated with an increased relative incidence of AKI compared
to unexposed periods (IRR = 1.20, 95% CI 1.15–1.26), with the greatest risk observed within 30 days following quinine
initiation (IRR = 1.48, 95% CI 1.35–1.61).
Conclusion: community prescriptions for quinine in an older adult population are associated with an increased risk of AKI.
Keywords: acute kidney injury, quinine, leg cramps, older people, epidemiology and pharmacovigilance
Key points
• Quinine is commonly prescribed to treat leg cramps
• Acute Kidney Injury (AKI) and leg cramps share a number of risk factors, and quinine itself can rarely precipitate AKI by
immune-mediated reactions
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Introduction
Acute kidney injury (AKI) is associated with a number of
negative outcomes including short- and long-term mortality
[1–3] and the development of chronic kidney disease (CKD)
[3, 4]. In the UK, one in 20 people over 70 years of age
experience an AKI each year [5] with the majority of AKI
cases developing in the community [6]. Identifying modifi-
able individual risk factors, such as nephrotoxic medications,
is an important target towards which preventative efforts
can be directed, particularly in the older population [7].
Cramps are sudden, painful, involuntary contractions of
muscles, typically occurring in the calf or foot, which affect
half of people over 80 years of age [8, 9]. Although usually
idiopathic, certain conditions and medications are associated
with leg cramps [8]. A number of these conditions overlap
with risk factors for AKI, notably the use of diuretics, CKD,
volume depletion and increased age [7, 10]. Quinine is the
most commonly prescribed medication in the UK and USA
to treat leg cramps [11, 12]. Quinine itself can precipitate
AKI by immune-mediated reactions, notably drug-induced
thrombotic microangiopathy (TMA) of which it is the most
common cause [13, 14]. Quinine-induced TMA is thought
to be mediated by antibodies that, in the presence of quinine,
target antigens on neutrophils and platelets [15]. Although
TMA is an uncommon adverse drug reaction, quinine-
induced TMA can be life-threatening with up to 90% of
individuals requiring dialysis [16]. Despite leg cramps shar-
ing a number of common risk factors with AKI, and quinine
itself known to affect the kidney by rare immune-mediated
reactions, the relationship between cramps, quinine and AKI
at a population level is unclear. The aim of this study is to
establish and quantify any observable association between
the exposure to community prescriptions for quinine and
AKI events in a population of older adults.
Methods
We performed two population studies using the same
dataset, a retrospective longitudinal cohort study and a self-
controlled case series (SCCS), of adults aged 60 years or
over who received community prescriptions for quinine
in Tayside, a region of Scotland with an approximate
population of 400,000. The study period was from 1 January
2004 to 31 December 2015. Further details on methodology
are described in Appendix 1.
First study design
The retrospective longitudinal study cohort included indi-
viduals who had received at least one prescription for quinine
and had at least two serum creatinine measurements more
than 7 days apart after the age of 60 years. A unique follow-
up period was calculated for each individual. Follow-up
started on the date of the first prescription for quinine or
creatinine measurement after the age of 60 years, whichever
was earlier, and ended at the end of the study period, death
or the date that an individual commenced renal replacement
therapy (RRT), whichever occurred first. People receiving
RRT at the start of the study period were not included.
Quinine exposure and episodes of care
The first study design examined the risk of AKI with quinine
exposure during ‘episodes of care’. As individuals may have
repeated creatinine measurements clustered around a period
of illness, creatinine measurements within 7 days of each
other were grouped into episodes of care. The 12 weeks
prior to each episode of care were examined to identify the
presence or absence of community prescriptions for quinine
(Appendix 2). The presence of any quinine prescriptions
during this time period inferred quinine exposure, either
recent or current. The risk of AKI was compared between
the episodes of care with and without quinine exposure.
Statistical analysis
Demographic characteristics and comorbidities are pre-
sented as counts and percentages for categorical variables and
means and standard deviations or medians and interquartile
ranges (IQRs) for quantitative data. A logistic regression
model for repeated measures binary data was used to examine
the association between quinine prescribing and the risk
of AKI. The size of the association was estimated based on
odds ratios (ORs), unadjusted and adjusted for demographic
characteristics, comorbidities and medication prescribed in
the 12 weeks prior to the episode of care. The follow-up
time from the start of the study period to the index episode
of care and the residual numbers of episodes of care until the
index episode (after adjustment for follow-up time) were also
included to try and account for the frequency of creatinine
measurements that varied between individuals. The model
estimates were calculated with clusters defined by patient
anonymised identification number to account for correlation
in the data. Model variable selection was carried out using
the quasi-likelihood information criterion. All analyses were
performed using SAS 9.4 [17].
Second study design
A second study, an SCCS, was also performed to explore fur-
ther the relationship between the use of quinine and AKI in
older people. The SCCS method can be used to study acute
recurrent outcomes and transient exposures for which exact
timings are available. Individuals act as their own controls
with follow-up time divided into periods with and without
exposure [18]. The effects of time-invariant confounders,
such as sex, location and underlying state of health, are
therefore eliminated [18]. The SCCS design has been used
previously to examine the relationship between community
antibiotic prescribing and AKI [19]. To be included in the
SCCS method, individuals must experience the exposure
and the outcome of interest; therefore, only individuals from
the first study cohort who experienced an AKI during follow-
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and follow-up were otherwise the same, with observation
starting on the date of the first prescription for quinine or
creatinine measurement after the age of 60, whichever was
earlier, and ending at the end of the study period, death
or the date that an individual commenced RRT, whichever
occurred first. The observation period for each individual was
divided into 5-year age categories (60–64, 65–69, 70–74,
75–79, 80–84, 85–89 and 90+ years). Exposure risk periods
(i.e. time periods ‘on’ quinine) started on the date of quinine
prescription and ended on the date of prescription + [1.5
× number of tablets dispensed] as 93.7% of prescriptions
contained directions that one quinine tablet should be taken
once daily. If an individual had successive quinine prescrip-
tions leading to overlapping time periods ‘on’ quinine, these
were merged together into a single time period. All other
follow-up time in each age category represented baseline
time ‘off’ quinine. The exposure risk periods ‘on’ and ‘off’
quinine were further subdivided into initiation and pre-
exposure periods, respectively (Appendix 3). The initiation
period comprised of the first 30 days after quinine prescrip-
tion. The pre-exposure period comprised of the 30 days
prior to quinine prescription. The date of the first creatinine
measurement of an episode of care was used as the date of the
AKI event. Incidence rate ratios (IRRs) and 95% confidence
intervals (CIs) were calculated comparing the incidence of
AKI during the different risk periods, assuming a Poisson
distribution and adjusting for age category [20]. All analyses
were performed using SAS 9.4 [17].
SCCS sensitivity analyses
The SCCS method assumes that recurrent outcomes occur
independently [18]. AKI increases the risk of an individ-
ual experiencing a further AKI. We therefore conducted
a sensitivity analysis that examined first AKI events only
[18]. People who had experienced an AKI prior to the start
of follow-up (according to creatinine measurements from
January 2003) were removed, and only the first AKI during
follow-up was included in this analysis. Furthermore, when
using the SCCS method, the occurrence of an event should
not censor the observation period [18]. AKI is associated
with mortality and developing the need for RRT. A sec-
ond sensitivity analysis was performed excluding individu-
als for whom follow-up ended within 90 days of an AKI
event [18].
Results
Between January 2004 and December 2015, there were
273,596 prescriptions for quinine dispensed to 16,750 peo-
ple in Tayside. The distribution of quinine prescriptions over
the time period is shown in Appendix 4.The median age at
first prescription was 69.7 years (IQR 59.5–77.9).
A total of 12,744 people fulfilled the inclusion criteria
and were included in the first study cohort. The cohort
was predominantly female (62.5% female) with a median
age of 70.5 years (IQR 63.9–77.4) at the start of follow-
up. Baseline characteristics are outlined in Table 1. A total
Table 1. Baseline characteristics of the first study cohort
Variable Frequency (%)
N = 12,744
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sex Female 7,968 (62.5)
Male 4,776 (37.5)
Age Median (IQR) 70.5
(63.9–77.4)






Follow-up Median in years (IQR) 9.7 (6.2–11.5)
RRT during study period 39 (0.31)
Died during study period 5,037 (39.5)
Quinine prescriptions Total 233,111
Median per person (IQR) 6 (1–27)
Episodes of care Total 267,900
Median per person (IQR) 18 (10–27)
CKD status eGFR > 60 11,419 (89.6)
eGFR 30–60 1,201 (9.4)
eGFR 15–30 117 (0.9)
eGFR < 15 7 (0.1)
History of previous AKI Nil 12,120 (95.1)
Stage 1 470 (3.7)
Stage 2 111 (0.9)
Stage 3 43 (0.3)
Comorbidities Type 1 diabetes mellitus 34 (0.3)
Type 2 diabetes mellitus 1,574 (12.4)
Myocardial infarction 606 (4.8)




Cerebrovascular disease 573 (4.5)
Liver disease 101 (0.8)
Abbreviations: eGFR, estimated glomerular filtration rate (ml/min per 1.73
m2); SIMD, Scottish Index of Multiple Deprivation (Quintiles 1-most
deprived, 5-least deprived). IQR presented as Q1–Q3. Age and comorbidities
at start of follow-up.
of 5,037 individuals (39.5%) in the cohort died during
the study period and 39 people (0.3%) commenced RRT.
People in the cohort had a significant number of comorbidi-
ties that increased throughout follow-up with subsequent
episodes of care. The prevalence of CKD increased from
10 to 47% by the end of follow-up and the number of
people with a history of myocardial infarction, heart failure,
cerebrovascular disease or peripheral vascular disease more
than tripled.
Episodes of care and incidence of AKI
A total of 267,900 episodes of care occurred during follow-
up. A summary of characteristics by episode of care is pre-
sented in Appendix 7. A total of 5,907 people (46.4%) in
the study cohort experienced an AKI during follow-up. Of
these individuals, the median number of AKI episodes was 2
per person (IQR 1–3). The overall incidence rate of AKI was
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Table 2. Unadjusted and adjusted OR of AKI by variable
Variable Unadjusted OR (95% CI) Adjusted OR (95% CI)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Quinine exposure 1.45 (1.39–1.53) 1.27 (1.21–1.33)
Demography Age (per 5-year increase) 1.25 (1.23–1.27) 1.18 (1.16–1.21)
Sex M vs F 1.01 (0.95–1.07) 1.07 (1.01–1.12)
SIMD 0.97 (0.95–0.99) 0.97 (0.95–0.99)
Number and time of episode Time of episode (per 1-year increase) 1.03 (1.02–1.04) 0.99 (0.98–1.00)
Number of episodes of care 1.01 (1.01–1.01) 0.99 (0.99–1.00)
History of previous AKI Stage 1 2.88 (2.74–3.02) 2.23 (2.11–2.35)
Stage 2 4.14 (3.83–4.47) 3.01 (2.77–3.28)
Stage 3 4.69 (3.98–5.54) 3.69 (3.14–4.34)
CKD status eGFR 30–60 1.93 (1.83–2.03) 1.16 (1.09–1.22)
eGFR 15–30 2.88 (2.65–3.13) 1.19 (1.08–1.31)
eGFR < 15 5.48 (3.51–8.57) 2.73 (1.65–4.54)
Other prescriptions ACEI 1.04 (0.99–1.10) 0.98 (0.93–1.02)
ARB 0.92 (0.86–0.99) 0.91 (0.85–0.97)
Diuretic 1.66 (1.57–1.76) 1.19 (1.12–1.25)
NSAID 0.95 (0.89–1.02) 1.29 (1.21–1.38)
Trimethoprim 2.28 (2.14–2.43) 1.87 (1.76–1.99)
Number of other drugs 1.13 (1.12–1.14) 1.05 (1.04–1.07)
Comorbidities Type 1 diabetes mellitus 1.38 (0.86–2.21) 1.34 (0.96–1.86)
Type 2 diabetes mellitus 1.07 (1.00–1.14) 0.87 (0.82–0.92)
Myocardial infarction 1.83 (1.71–1.96) 1.11 (1.04–1.19)
Heart failure 2.65 (2.48–2.84) 1.45 (1.36–1.55)
Peripheral vascular disease 2.19 (2.03–2.35) 1.37 (1.28–1.47)
Cerebrovascular disease 2.02 (1.89–2.17) 1.35 (1.27–1.44)
Liver disease 1.89 (1.61–2.23) 1.61 (1.35–1.93)
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; eGFR, estimated glomerular filtration rate (ml/min per 1.73
m2); NSAID, non-steroidal anti-inflammatory drug; SIMD, Scottish Index of Multiple Deprivation (1-most deprived, 5-least deprived). Trimethoprim refers to
trimethoprim-containing antibiotics including co-trimoxazole. Age at start of follow-up. Time of episode is from start of study period until episode of care. Number
of episodes of care is the number of previous episodes of care until the index episode using residuals after adjustment for time of episode.
Risk of AKI associated with quinine exposure
Crude and adjusted ORs for the association between AKI
and each variable modelled in the first study design are
presented in Table 2. The crude and adjusted ORs for the
risk of AKI occurring during an episode of care with exposure
to quinine was OR 1.45 (95% CI 1.39–1.53) and OR 1.27
(95% CI 1.21–1.33), respectively.
Second study design
The SCCS study included the 5,907 individuals who expe-
rienced an AKI in the first study cohort. Baseline charac-
teristics of the SCCS cohort are outlined in Appendices 8
and 9. The cohort was predominantly female (62.6% female)
with a median age of 73.6 years (IQR 67.1–79.8) at the
start of follow-up. During the observation period, a total of
13,616 AKI events occurred. The baseline incidence rate of
AKI ‘off’ quinine was 26.7 events per 100 person-years. Total
follow-up time ‘on’ quinine was 14,535 years compared to
33,378 years ‘off’ quinine.
IRRs
The crude and adjusted IRRs of AKI associated with
quinine exposure periods were IRR 1.21 (95% CI 1.15–
1.27) and IRR 1.20 (95% CI 1.15–1.26), respectively.
Table 3. IRRs of AKI during subdivided time periods
Time periods Adjusted IRRs (95% CI)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Baseline time period 1.00
Total ‘on’ period vs Total ‘off’ period 1.20 (1.15, 1.26)
Initiation period vs Remainder of ‘on’ period 1.26 (1.15, 1.38)
Initiation period vs Baseline ‘off’ quinine 1.48 (1.35, 1.61)
Remainder of ‘on’ period vs Baseline ‘off’ quinine 1.17 (1.11, 1.23)
Pre-exposure period vs Baseline ‘off’ quinine 0.98 (0.88, 1.09)
IRR adjusted for age category. The initiation period comprised the first 30 days
after quinine prescription. The pre-exposure period comprised the 30 days prior
to quinine prescription.
The adjusted IRR remained significant following sensitivity
analyses restricted to first AKI events only (5,471 individuals,
IRR = 1.21, 95% CI 1.15–1.26) and removal of individuals
who experienced AKI within 90 days of the end of follow-up
(3,541 individuals, IRR = 1.27, 95% CI 1.19–1.34). When
the initiation and pre-exposure risk periods were examined,
the IRR for AKI was greatest within 30 days following
quinine initiation (IRR = 1.48, 95% CI 1.35–1.61, Table 3).
There was no difference in the relative incidence of AKI
during the pre-exposure period compared to the baseline
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Discussion
To our knowledge, this is the first study to examine the
association between quinine exposure and AKI at a popu-
lation level. We observed a significant association between
quinine exposure and AKI in an older population aged
60 years or over using two different study designs applied
to the same dataset. In a retrospective longitudinal cohort
study examining episodes of care among 12,744 individu-
als who received community prescriptions for quinine, we
found that a prescription for quinine was independently
associated with a 27% increased risk of AKI. Similarly,
the SCCS demonstrated a 20% increased risk, with qui-
nine initiation being associated with the greatest increased
risk of 48%.
Our study has a number of strengths. In our first study
design, we examined the association using a large population
cohort with median follow-up period of 10 years. By the
very nature of its indication, people prescribed quinine for
cramps are typically older with comorbidities and other pre-
scribed medications. Access to large national datasets linked
by anonymised individual identifiers allowed us to generate
a comprehensive profile of an individual’s demographics,
comorbidities, community prescriptions and baseline renal
function. Adjustment was made based on this information
at the time of each episode of care, thereby accounting
for the progressive nature of comorbidity in our cohort.
Furthermore, the findings of our initial study were supported
by the second study design, an SCCS with the results of
sensitivity analyses in keeping with the main findings.
However, our study has its limitations inherent to obser-
vational studies. Firstly, potentially relevant variables, such
as smoking status and medical conditions diagnosed with-
out hospital admission, would not have been captured by
our datasets with potential for unmeasured confounding.
Secondly, people in our cohort were required to have had
creatinine measurements, and testing was inconsistent with
some individuals undergoing regular blood tests while others
had infrequent and distant serum creatinine measurements.
To try and account for this, we adjusted for the residual
numbers of episodes of care until the index episode (after
adjustment for follow-up time). This adjusted for the num-
ber of previous episodes of care (i.e. the number of blood
tests) without repeating the adjustment for time of episode
since the two were closely correlated. Thirdly, whether or not
a medication is taken regularly as prescribed from the date of
prescription cannot be determined from observational data.
In our first study design, a prescription for quinine within the
12 weeks prior to an episode of care was used to infer recent
or current exposure as the majority of quinine prescriptions
were either for 28 or 56 tablets. Misclassification of current
exposure remains a possibility. Finally, our study is only based
within one NHS health board in Scotland, which could
affect the generalisability of our results. However, individuals
in this region are broadly representative of the national
population as a whole, so it is unlikely that our findings
would significantly differ.
In the UK, quinine is most commonly prescribed for the
treatment of leg cramps but has limited efficacy [8]. Leg
cramps are associated with a number of conditions and medi-
cations that are also risk factors for AKI, including diuretics,
CKD and increased age [8]. For example, leg cramps can
occur in the context of volume depletion that may in turn
be associated with a prerenal hypoperfusion-related AKI. A
degree of overlap is therefore possible and cramps may repre-
sent a state of physiological vulnerability. However, quinine
itself is also known to affect the kidney through immune-
mediated reactions including drug-induced TMA [13]. In
one case series of 19 people with confirmed quinine-induced
TMA, each person experienced AKI without pre-existing
CKD, one individual died and 17 of the remaining 18
required dialysis, three of whom required RRT indefinitely
[16]. Although this infrequent acute syndrome is unlikely to
confer risk of AKI at a population level, the mechanism of
a quinine-dependant antibody reaction could be considered.
Other effects of quinine on the cardiovascular system may
also play a role. Quinine, the stereoisomer of quinidine,
may increase myocardial conduction time and prolong QT
interval [21, 22]. It also possesses alpha-adrenergic blocking
properties that can predispose to hypotension [23]. In a Dan-
ish study of people with heart failure, quinine was associated
with an increased risk of death, particularly with concurrent
β-blocker therapy [24]. Side effects of quinine can occur at
therapeutic doses and include tinnitus, hearing impairment,
headache, nausea, vertigo and visual disturbance [8]. Drug
interactions can also occur [25]. Older people may be more
susceptible to these effects due to an increased elimina-
tion half-life associated with age [26] and more prevalent
polypharmacy.
Primarily in response to the risk of immune-mediated
reactions, regulatory bodies such as the Food and Drug
Administration (FDA) and the Medicines and Healthcare
products Regulatory Agency (MHRA) have discouraged the
prescription of quinine as symptomatic treatment for leg
cramps [12, 25]. The MHRA advises that quinine should
not be used routinely, its effectiveness should be continually
reassessed and trials of treatment discontinuation consid-
ered [25]. However, our findings suggest a novel associa-
tion between community quinine prescriptions and AKI in
an older population that is unlikely to be simply related
to rare immune-mediated reactions. Whether this relation-
ship is directly related to quinine or the underlying mech-
anism causing leg cramps remains unclear. Nevertheless,
the results of our study support the guidance from the
FDA and MHRA. Our findings also highlight to healthcare
professionals that patients presenting with cramps should
receive careful consideration of the underlying cause, which
may be a modifiable risk factor for AKI, prior to initiat-
ing symptomatic management. More research is required
to characterise further the relationship between quinine,
cramps and AKI.
Supplementary Data: Supplementary data mentioned in
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